TRAcking Thoracic Cancer Evolution Through Therapy (Rx) EVO
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity College, London
About this trial
TRACERx EVO is a programme of work using a prospective observational cohort study of participants with early- and late-stage non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC) and pleural mesothelioma.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Written Informed consent
Agreement to be followed up (including on-study assessments and sample collection) every 3 months in the first 2 years and then 6 monthly.
Agreement to be followed up at a TRACERx EVO site
Participants ≥18 years of age, with early stage I-IIIB NSCLC disease who are eligible for primary surgery
Disqualifiers
Other active malignancy
Any other* malignancy diagnosed or relapsed at any time, which is currently being treated (including by hormonal therapy).
Any other* current malignancy or malignancy diagnosed or relapsed within the past 3 years**.
*Exceptions are: non-melanomatous skin cancer, stage 0 melanoma in situ, and in situ cervical cancer
Trial population
I-IIIC or de novo metastatic (stage IV) Non-small cell lung cancer, stage I-IV Small cell lung cancer, pleural mesothelioma.
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
600 Participants
are grouped into 3 trial groupsGroup A: Cohort A
Group B: Cohort B
Group C: Cohort C
Trial outcomes
Primary outcomes
1
Disease Free Survival
DFS; recurrence or death from any cause): Cohorts A \& C
Time frame
5 years2
Progression Free Survival
PFS; first disease progression or death from any cause): Cohorts B \& C
Time frame
5 years3
Overall Survival
Time frame
5 yearsSponsors and contacts
Click on the lead sponsor to view all of their trials.
University College, London
Lead sponsor
Cancer Research UK
Collaborator
Source ClinicalTrials.gov